HNF1B and endometrioid adenocarcinoma: Stated another way, 33.3% of carcinosarcomas, 66.7% of clear cell carcinomas, 13.7% of endometrioid carcinomas, 40% of mixed type tumors, and 31.6% of serous carcinomas stained positively for HNF1β.